Kimera Labs is an FDA registered lab located in Miramar, Florida. We are the largest exosome focused company in the world with 27,000 sq ft, 50 employees and exosome qualification via spectrophotometry, particle analysis, dSTORM visualization, RNA quantification, Flow Cytometry, Elisa Analysis, Western Blot, Visual qualification, Mass Spectrometry, EM, AFM, and adherence to FDA guidances.
In 2002, my Oceanographer father and I were faced with an almost impossible decision. The chemotherapy we were using to treat his leukemia was no longer functional, and we were forced to choose an immunological approach, bone marrow stem cell transplantation (BMT), for which the rate of survival was 50%. We hesitated for so long that when we finally decided on BMT he was no longer eligible. I clearly remember meekly, and humiliatingly, offering a well known transplant expert, Dr. Karen Ballen at Massachusetts General Hospital, a paper on Copper supplementation for the treatment of AML. She politely thanked me and raised her hand in a negative response. After this encounter, and two years before his death, I enrolled in the Ph.D. program at the University of Miami. I obtained an 8 year dual education in the departments of biochemistry and immunology and I am today still trying to control disease using immunological molecular approaches. One of the directions that showed early promise in chronic GVHD after BMT was the use of mesenchymal stromal cells to suppress rejection. My study of immunological manipulation, in concert with the understanding I developed in 2014 of what the 'paracrine effect' of cell communication really means (exosomes), has led our company down a path that has resulted in multiple FDA IND applications in process, and our position as one of the most well respected groups in exosome science.
I am happy to contribute to the body of knowledge of exosome research. Feel free to ask us for our protein, mRNA, or miRNA research results that help us define the evolving science that is cellular signalling.
Duncan Ross Ph.D.
Kimera Labs Inc. is a biotechnology laboratory that develops perinatal exosome products for research and therapeutic purposes. Since 2012, Kimera Labs and Kimera Society have invested significant resources into exosome isolation protocols for the field of regenerative medicine.
Functioning within two physical spaces totaling over 27,000 sq ft in Miramar, Florida, we feature ISO 5 isolator hoods, class 7 cleanrooms, in-house particle characterization via first in class redox based nano imaging, NanoSight, protein concentration, HPLC, RNA sequencing and flow cytometry.
As a regenerative medicine focused biotechnology company founded by a published scientist, Kimera Labs develops therapies that harness the power of stem cells, without the use of the cells themselves. By providing regenerative cellular signals under the control of messenger and micro RNA, we believe it is possible to instantiate healing processes that can benefit patients of any age.
Kimera Labs is located in Miramar, Florida. Kimera Labs Amnio2 amniotic fluid product falls under 361 tissue product regulation. Kimera Labs XoGlo™ exosome product is for topical use only.
Unlike other laboratories, Kimera goes above and beyond FDA requirements for viral testing. We test for Zika, CMV, EBV, Hepatitis E, HBV, HCV, HIV, HHV6, HHV7, HHV8, HSV1&2, HTLV1, HTLV2, BKV, and Norovirus AFTER MANUFACTURE, under quarantine, and prior to release. As with any other tissue bank, we test the donor mother's serum for: